October 16, 2009 — Clinicians should consider magnetic resonance imaging (MRI) for men who have elevated prostate-specific antigen (PSA) levels or some other "worrisome" prostate cancer variable, but ...
Hosted on MSN
New MRI scan could detect prostate cancer in minutes
Millions of men could benefit from a new, faster prostate cancer scan. The quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer in clinical trials as the current 30- to ...
There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...
Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...
Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...
A pretreatment MRI in men undergoing radical prostatectomy can provide independent prognostic value for oncologic outcomes, a systematic review and meta-analysis indicated. MRI-detected extraprostatic ...
An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...
Biparametric MRI, which omits the dynamic contrast enhancement sequence, can detect clinically significant prostate cancer as well as multiparametric MRI. Biparametric MRI performs as well as ...
International experts have recommended quick and targeted MRI scans for prostate cancer screening. Some 21 urologists, radiologists and pathologists from Europe and the US agreed an "expert consensus ...
A phase 3 trial found that PSMA PET-CT after equivocal MRI halves the prostate biopsy rate in men at high clinical risk for prostate cancer. In men with high clinical risk and equivocal prostate ...
EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX (R) platform, today announced the publication of a ...
GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results